Undergraduate honors paper--Mount Holyoke College, 2008. Dept of Social Sciences. / Includes bibliographical references (leaves 66-76).

Thesis (Ph.D.)--Drexel University, 2008. / Includes abstract and vita. Includes bibliographical references (leaves 83-91).

Thèse--Méd.--Reims, 1976. N°: N° 102. / Bibliogr. f. 76-82.

Thesis (Ph. D.)--University of Texas at Austin, 2001. / Vita. Includes bibliographical references. Available also in a digital version from UMI/Dissertation Abstracts International.

Thesis (M.S.)--Ball State University, 2009. / Title from PDF t.p. (viewed on June 08, 2010). Includes bibliographical references (p. 39-42).

Thesis (PH. D.)--University of Chicago, 1936. / Lutheprinted. "Private edition, distributed by the University of Chicago libraries, Chicago, Illinois."

Thesis (M. Phil.)--University of Hong Kong, 2005. / Title proper from title frame. Also available in printed format.

Thesis (M.S.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 43 pages. Includes Vita. Includes bibliographical references.

Made available in DSpace on 2013-08-07T19:03:30Z (GMT). No. of bitstreams: 1 000412124-Texto+Completo-0.pdf: 410403 bytes, checksum: 0cf00f9b1e8cfc14127a3fbbfa89e419 (MD5) Previous issue date: 2009 / Nutritional and metabolic profile in patients with systemic lupus erythematosus – SLE is not widely approached in literature. A possible association of antimalarial therapy and corticotherapy with metabolic alterations is the scope of discussion in SLE. This transversal study describes nutritional and metabolic profile in patients with SLE from a reference center as well as it evaluates possible interactions of antimalarial and steroids therapy with nutritional and metabolic variables. Sixty patients with SLE – in accordance to the 1997 criteria – were initially evaluated. Smoking habit and systemic arterial hypertension were studied in all patients. Nutritional evaluation comprised anthropometric measurements (weight, height and abdominal circumference), while metabolic evaluation comprised total cholesterol levels and HDL fractions. All patients were evaluated as for the use or not of chloroquine and corticosteroids. From the sixty patients with SLE, 57 (95%) were female, mainly white. Total age average was 48. 7 years old. Average length of disease in women was 9. 1 years. Hypertension and smoking habit were detected in 61. 6% and 26. 7% of all cases respectively. Average body mass index – BMI (kg/m2) was 25. 5 in females showing overweight. Average abdominal circumference, which is a measure of metabolic risk, was also found altered in women (89. 8 cm). Increased abdominal circumference was associated with overweight (p < 0. 001). Overweight was not associated with hypertension or total cholesterol levels and HDL levels alterations (p > 0. 05). There was not a significant association between smoking habit and abdominal circumference alterations (p > 0. 05).Use of chloroquine and corticosteroids was not associated with lipid profile abnormalities, as there was no association between corticotherapy and BMI alterations (p > 0. 05). As a whole, lupus population presented overweight and metabolic risk. Overweight did not relate to hypertension or lipid profile alterations, smoking habit did not trigger metabolic risk increase. Use of chloroquine did not protect against hypercholesterolemia, and patients with corticotherapy did not present significant lipid profile and BMI alterations. / O perfil metabólico e nutricional de pacientes com LES é pouco abordado na literatura. A possível associação da terapia antimalárica e da corticoterapia com alterações metabólicas é motivo de discussão no LES. Este estudo, transversal, descreve o perfil nutricional de pacientes com LES de um centro de referência; avalia, também, as possíveis interações da terapia antimalárica e esteroide com variáveis nutricionais e metabólicas. Sessenta pacientes com LES, de acordo com os critérios de 1997 foram avaliados. Hábito tabágico e ocorrência de hipertensão arterial sistêmica (HAS) foram estudados em todos os pacientes. A avaliação nutricional compreendeu a antropometria (peso, altura e circunferência abdominal), enquanto a avaliação metabólica incluiu níveis de colesterol total e fração HDL. Todos os pacientes foram avaliados quanto ao uso ou não de cloroquina e corticosteroides. Dos 60 pacientes com LES, 57 (95%) eram do sexo feminino; a raça branca predominou (88,3%). A média global de idade foi de 48,7 anos. A duração média da doença lúpica foi de 9,1 anos no sexo feminino. Hipertensão e tabagismo foram detectados em 61,6% e 26,7% dos casos, respectivamente. O índice de massa corporal –IMC (kg/m2) , médio foi de 25,5 no sexo feminino, indicando sobrepeso. A média da circunferência abdominal, medida de risco metabólico, foi também alterada em mulheres (89,8 cm). Circunferência abdominal aumentada se associou a sobrepeso (p < 0,001). O excesso de peso não se associou à ocorrência de HAS ou alterações de colesterol total e HDL (p > 0,05). Não houve associação significante entre hábito tabágico e alterações de circunferência abdominal (p > 0,05).O uso de cloroquina e corticosteroides não se associou a anormalidades da colesterolemia; igualmente, não houve associação entre corticoterapia e alterações de IMC (p > 0,05). Como um todo, nossa população de lúpicas apresentou sobrepeso e aumento de risco metabólico. O excesso de peso não se relacionou a HAS ou alterações de perfil lipídico, e o hábito tabágico não deflagrou aumento de risco metabólico. O uso de cloroquina não foi protetor para hipercolesterolemia, e pacientes sob corticoterapia não apresentaram alterações significativas de colesterolemia e IMC.

Systemic Lupus Erythematosus (SLE) is an autoimmune disease with chronic inflammation affecting multiple organ systems, as well as accelerated atherosclerosis as a major complication. Prior studies by our lab have shown beneficial effects of PPARgamma agonists towards preventing SLE in two different mouse models: the well-established lupus mouse model, MRL.lpr, and the gld.apoE^-/- model of accelerated lupus and atherosclerosis. Retinaldehyde is a retinoic acid precursor that has recently been shown to inhibit PPARgamma signaling in adipose tissue. We proposed that abnormal accumulation of retinaldehyde in lupus promotes autoimmunity by inhibition of PPARgamma signaling. We measured the serum retinaldehyde levels in both lupus mouse models using reversed-phase high-performance liquid chromatography. We also examined the mRNA expressions of genes involved in retinaldehyde metabolism and PPARgamma signaling in white adipose tissues using real-time quantitative PCR. We observed a higher level of circulating retinaldehyde in the MRL.lpr mouse model on a chow diet. The circulating retinaldehyde levels in both .gld.apoE^-/- and C57 increased when maintained on a high-cholesterol Western diet. Within visceral and subcuntaneous adipose tissue, we saw several changes to expression of the genes responsible for retinaldehyde synthesis and catabolism, however further study is required to definitively assess the role of these genes. Importantly, the expression levels of genes involved in PPARgamma signaling decreased in the subcutaneous fat of gld.apoE^-/- mice on a Western diet. Our data suggest that retinaldehyde may play a role in SLE pathogenesis and could be a potential therapeutic target for SLE.